B-cell chronic lymphocytic leukemia. Part V. Stem cell transplantation


Authors: T. Papajík;  L. Raida;  E. Faber;  K. Indrák
Authors‘ workplace: Hemato-onkologická klinika FNO a LF UP v Olomouci
Published in: Transfuze Hematol. dnes,13, 2007, No. 3, p. 100-105.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Despite recent therapeutic advances B-cell chronic lymphocytic leukemia (B-CLL) still represents an incurable disease with standard therapy. Early results of autologous stem cell transplantation (ASCT) suggested a significant proportion of patients remained disease-free for years, raising the possibility of cure. However, recent studies have shown no evidence of a plateau in the disease-free curves indicating incurability of B-CLL with ASCT. Initial results of allogeneic stem cell transplantation (allo-SCT) with myeloablative conditioning were disappointing due to the high transplant-related mortality, but led to long-term remission and possible cure in a significant proportion of relapsing and refractory patients. The availability of reduced-intensity conditioning (RIC) has resulted in increased use of allo-SCT and decreased early transplant-related mortality. In this setting the majority of anti-leukemia effect results from the graft-versus-leukemia reaction and not from the chemo- or radiotherapy. It should be point out that it remains too early to determine the long-term results of RIC allo-SCT with regard to morbidity of chronic graft-versus-host disease and disease control.

Key words:
B-cell chronic lymphocytic leukemia, allogeneic, autologous, stem cell transplantation


Sources

1. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 1999; 94: 448–454.

2. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol – A Groupe d’Etude des Lymphomes de l’Adulte Study. J Clin Oncol 2000; 18: 3025–3030.

3. Milpied N, Deconinck E, Gaillard F, et al. Initial Treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.

4. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

6. Rabinowe SN, Soiffier RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic leukemia. Blood 1993; 82: 1366–1376.

7. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.

8. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228–2235.

9. Gribben JG, Neuberg D, Soiffer RJ, et al. Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis chronic lymphocytic leukemia. Blood 1998; 92 (suppl. 1): 1320a.

10. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.

11. Meloni G, Proia A, Mauro FR, et al. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring. Haematologica 2000; 85: 952–960.

12. Dreger P, Viehmann K, von Neuhoff N, et al. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp Hematol 2000; 28: 1187–1196.

13. Michallet M, van Biezen A, Bandini G, et al. Analysis of prognostic factors on the outcome of autologous and allogeneic transplantation for chronic lymhocytic leukemia. Blood 2001; 98: 859a.

14. Esteve J, Monteserrat E, Dreger P, et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogeneic transplants. Blood 2001; 98: 482a.

15. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850–2858.

16. Milligan D, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397– 404.

17. Milligan DW, Kochetchu G, Dearden C, et al. High incidence of myelodysplasia and secondary leukemia in the UK Medica Reysearch Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006; 133: 173–175.

18. Jarque I, Palau J, Sanz GF, et al. Delayed complete response after allogeneic bone marrow transplantation in chronic lymphocytic leukaemia. Blood 1993; 82, 1036–1038.

19. Mehta J, Powles R, Singhal S, et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17: 371-375.

20. Mattson J, Uzunel M, Ljungman P, et al. Minimal residual diseaseis common after allogeneic stem cell transplantation in patients with B-cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000; 14: 245–254.

21. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukaemia. Annual Internal Medicine 1996; 124: 311–315.

22. Michallet M, Carreras E, Cornelissen JJ. Allotransplants and autotransplants in CLL. Bone Marrow Transplant 1999; 23 (supp.1): S53.

23. Horowitz MM, Monstserrat E, Sobocinski K, et al. Haematopoietic stem cell transplantation for chronic lymphocytic leukemia. Blood 2000; 96 (suppl. 1): 2245.

24. Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J Clin Oncol 2005; 23: 5788–5794.

25. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001; 15: 445–451.

26. Ritgen M, Stilgenbauer S, Neuhoff NV, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602.

27. Khouri IF, Przepiorka D, Besien KV, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466–473.

28. Dreger P, Brand R, Hansz J, et al. Treatment related mortality and graft versus leukemia effect after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity reduced conditioning. Leukemia 2003; 17: 841–848.

29. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

30. Delgado J, Thomson K, Russel N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724–1730.

31. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819–3829.

32. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029-1033.

33. Caballero D, Garcia-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities. Clin Cancer Res 2005; 11: 7757–7763.

34. Brown JR, Haesook TK, Shuli L, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advance chronic lymphocytic leukemia. Biol Blood Marrow Transpl 2006; 12: 1056–1064.

35. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17.

Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 3

2007 Issue 3

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account